• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Immunocore Holdings plc

    5/7/25 4:38:41 PM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMCR alert in real time by email
    S-8 1 ef20048500_s8.htm S-8
    As filed with the Securities and Exchange Commission on May 7, 2025
    Registration No. 333-

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933


    Immunocore Holdings plc
    (Exact name of registrant as specified in its charter)


    England and Wales
     
    Not applicable
    (State or other jurisdiction of Incorporation or organization)
     
    (I.R.S. Employer Identification No.)
     
    92 Park Drive
    Milton Park
    Abingdon, Oxfordshire OX14 4RY
    United Kingdom
    (Address of principal executive offices) (Zip code)


    Immunocore Holdings plc 2021 Equity Incentive Plan, with Non-Employee Sub-Plan
    (Full title of the plan)


    Immunocore, LLC
    Six Tower Bridge, Suite 200
    181 Washington Street
    Conshohocken, Pennsylvania 19428
    United States
    Tel: +1 484 534 5261
    (Name and address of agent for service) (Telephone number, including area code, of agent for service)


    Copies to:

    Divakar Gupta
    Courtney T. Thorne
    Cooley LLP
    55 Hudson Yards
    New York, New York 10001
    +1 212 479 6000
     
    Lily Hepworth
    General Counsel
    Immunocore Holdings plc
    92 Park Drive
    Milton Park
    Abingdon, Oxfordshire OX14 4RY
    United Kingdom
    Tel: +44 12 3543 8600
     
    Claire Keast-Butler
    Cooley (UK) LLP
    22 Bishopsgate
    London EC2N 4BQ
    United Kingdom
    +44 20 7583 4055
     
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer
     
    ☒
     
    Accelerated filer
     
    ☐
    Non-accelerated filer
     
    ☐
     
    Smaller reporting company
     
    ☐
           
    Emerging growth company
     
    ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐



    REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E
     
    Pursuant to General Instruction E to Form S-8, Immunocore Holdings plc (the “Registrant”) is filing this Registration Statement on Form S-8 with the Securities and Exchange Commission (the “Commission”) to register 2,466,523 additional ordinary shares, nominal value £0.002 per share (the “Ordinary Shares”), of the Registrant under the Immunocore Holdings plc 2021 Equity Incentive Plan, with Non-Employee Sub Plan (the “2021 Plan”), pursuant to the provisions of the 2021 Plan providing for an automatic increase in the number of Ordinary Shares reserved and available for issuance under the 2021 Plan on January 1, 2025. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.
     
    PART II
     
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
     
    ITEM 3.
    INCORPORATION OF DOCUMENTS BY REFERENCE
     
    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:
     
    (a) The Registrant’s Registration Statements on Form S-8, filed with the Commission on April 12, 2021 (File No. 333-255182), May 17, 2022 (File No. 333-265000), April 6, 2023 (File No. 333-271164), and March 21, 2024 (File No. 333-278121);
     
    (b) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 26, 2025;
     
    (c) The Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Commission on May 7, 2025;
     
    (d) The Registrant’s Definitive Proxy Statement on Schedule 14A, filed with the Commission on April 4, 2025;
     
    (e) The Registrant’s Current Reports on Form 8-K filed with the SEC on January 2, 2025 (excluding Item 7.01 therein), January 10, 2025 (excluding Items 2.02 and 7.01 therein), February 26, 2025 (excluding Item 2.02 therein) and March 17, 2025; and
     
    (f) The description of the Registrant’s Ordinary Shares and American Depositary Shares contained in the Registrant’s Registration Statement on Form 8-A, filed with the Commission on February 2, 2021 (File No. 001-39992) under the Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description, including Exhibit 2.4 to the Registrant’s Annual Report on Form 20-F for the fiscal year ended December 31, 2020, filed with the Commission on March 25, 2021.
     
    (g) All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained or incorporated by reference herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
     
    1

    ITEM 8.
    EXHIBITS.
     
           
    Incorporated by Reference
    Exhibit
    Number
     
    Description
     
    Schedule
    Form
     
    File Number
     
    Exhibit
     
    Filing Date
    4.1
     
    Articles of Association of Immunocore Holdings plc.
     
    10-Q
     
    001-39992
     
    3.1
     
    8/8/24
    4.2
     
    Deposit Agreement.
     
    20-F
     
    001-39992
     
    2.2
     
    3/25/21
    4.3
     
    Form of American Depositary Receipt (included in Exhibit 4.2).
     
    20-F
     
    001-39992
     
    2.3
     
    3/25/21
    5.1*
     
    Opinion of Cooley (UK) LLP.
                   
    23.1*
     
    Consent of KPMG LLP, the Registrant’s former independent registered public accounting firm
                   
    23.2*
     
    Consent of Deloitte LLP, the Registrant’s independent registered public accounting firm
                   
    23.3*
     
    Consent of Cooley (UK) LLP (included in Exhibit 5.1).
                   
    24.1*
     
    Power of Attorney (included on the signature page of this Registration Statement)
                   
    99.1
     
    Immunocore Holdings plc 2021 Equity Incentive Plan, with Non-Employee Sub-Plan.
     
    20-F
     
    001-39992
     
    4.20
     
    3/25/21
    107*
     
    Filing Fee Table
                   


    *
    Filed herewith.
     
    2

    SIGNATURES
     
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Oxford, United Kingdom, on the seventh day of May, 2025.
     
     
    IMMUNOCORE HOLDINGS PLC
         
     
    By:
    /s/ Bahija Jallal, Ph.D.
       
    Name: Bahija Jallal, Ph.D.
       
    Title: Chief Executive Officer
     
    POWER OF ATTORNEY
     
    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Bahija Jallal, Travis Coy and Lily Hepworth, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
     
    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
     
    1

    SIGNATURE
     
    TITLE
     
    DATE
             
    /s/ Bahija Jallal, Ph.D.
     
    Chief Executive Officer and Director
     
    May 7, 2025
    Bahija Jallal, Ph.D.
     
    (Principal Executive Officer)
       
             
    /s/ Travis Coy
     
    Chief Financial Officer
     
    May 7, 2025
    Travis Coy
     
    (Principal Financial Officer)
       
             
    /s/ John Goll
     
    SVP, Finance & Chief Accounting Officer
     
    May 7, 2025
    John Goll
     
    (Principal Accounting Officer)
       
             
    /s/ Professor Sir John Bell
     
    Chairman of the Board of Directors
     
    May 7, 2025
    Professor Sir John Bell
           
             
    /s/ Roy S. Herbst, M.D., Ph.D.
     
    Director
     
    May 7, 2025
    Roy S. Herbst, M.D., Ph.D.
           
             
    /s/ Siddharth Kaul
     
    Director
     
    May 7, 2025
    Siddharth Kaul
           
             
    /s/ Mr. Ranjeev Krishana
     
    Director
     
    May 7, 2025
    Mr. Ranjeev Krishana
           
             
    /s/ Dr. William Pao, M.D., Ph.D.
     
    Director
     
    May 7, 2025
    Dr. William Pao, M.D., Ph.D.
           
             
    /s/ Robert Perez
     
    Director
     
    May 7, 2025
    Robert Perez
           
             
    /s/ Kristine Peterson
     
    Director
     
    May 7, 2025
    Kristine Peterson
           
             
    /s/ Professor Sir Peter Ratcliffe
     
    Director
     
    May 7, 2025
    Professor Sir Peter Ratcliffe
           

    2

    SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE
     
    Pursuant to the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of Immunocore Holdings plc has signed this registration statement or amendment thereto on May 7, 2025.

     
    IMMUNOCORE, LLC
         
     
    By:
    /s/ Bahija Jallal, Ph.D.
       
    Name: Bahija Jallal, Ph.D.
       
    Title: Authorized Signatory

     
    3

    Get the next $IMCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMCR

    DatePrice TargetRatingAnalyst
    12/13/2024$74.00 → $35.00Overweight → Equal-Weight
    Morgan Stanley
    11/11/2024$72.00 → $38.00Outperform → Neutral
    Mizuho
    10/24/2024$24.00Sell
    UBS
    10/7/2024Buy → Neutral
    Guggenheim
    4/29/2024$74.00Outperform
    Leerink Partners
    11/20/2023$60.00Overweight
    JP Morgan
    11/2/2023Overweight
    Cantor Fitzgerald
    10/31/2023$84.00Outperform
    Robert W. Baird
    More analyst ratings

    $IMCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immunocore reports first quarter financial results and provides a business update

      Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure candidate presented during oral session at CROI 2025; dose escalation ongoing Cash, cash equivalents and marketable securities of $837 million as of March 31, 2025 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, May 7, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Com

      5/7/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore to present at upcoming investor conferences

      Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 April 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in April.                   Kempen Life Sciences Conference                  1x1 and small group meetings: Thursday, April 3, 2025                   Needham Virtual Healthcare Conferen

      4/2/25 8:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025

      Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 IMC-M113V was well tolerated, with no dose-limiting toxicities Signals of dose-dependent reduction in active reservoir, and viral control after complete antiretroviral treatment interruption in some PLWH Enrollment in MAD portion of the trial continues with higher doses being evaluated (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 10 March 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically impr

      3/10/25 3:00:00 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Baker Bros. Advisors Lp bought $23,993,224 worth of American Depositary Shares (807,338 units at $29.72) (SEC Form 4)

      4 - Immunocore Holdings plc (0001671927) (Issuer)

      3/19/25 6:40:21 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Immunocore downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Immunocore from Overweight to Equal-Weight and set a new price target of $35.00 from $74.00 previously

      12/13/24 8:04:38 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore downgraded by Mizuho with a new price target

      Mizuho downgraded Immunocore from Outperform to Neutral and set a new price target of $38.00 from $72.00 previously

      11/11/24 7:41:04 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • UBS initiated coverage on Immunocore with a new price target

      UBS initiated coverage of Immunocore with a rating of Sell and set a new price target of $24.00

      10/24/24 6:22:17 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    Financials

    Live finance-specific insights

    See more
    • Immunocore reports first quarter financial results and provides a business update

      Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure candidate presented during oral session at CROI 2025; dose escalation ongoing Cash, cash equivalents and marketable securities of $837 million as of March 31, 2025 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, May 7, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Com

      5/7/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore reports fourth quarter and full year 2024 financial results and provides a business update

      KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025 Executing on KIMMTRAK lifecycle management with two Phase 3 trials (TEBE-AM and ATOM) in additional melanoma indications Advancing PRAME portfolio – first patient randomized in Phase 3 PRISM-MEL-301; enrollment continues in Phase 1/2 trial of brenetafusp combinations in ovarian cancer and NSCLC; first patient dosed in Phase 1 trial of IMC-P115C (PRAME-A02-HLE) First patient dosed in Phase 1/2 trial of IMC-R117C (PIWIL1) in colorectal and other gastrointestinal cancers Will present initial Phase 1 multiple ascending dose HIV data for IMC-M113V in 1Q 2025 and Phase

      2/26/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025

      (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 19 February 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the fourth quarter and year ended December 31, 2024 on Wednesday, February 26, 2025. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) to discuss its financial results and provide a business and portfolio u

      2/19/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Immunocore Holdings plc

      SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)

      11/14/24 1:28:34 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immunocore Holdings plc

      SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)

      11/14/24 1:22:39 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immunocore Holdings plc

      SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)

      11/14/24 6:40:08 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    Leadership Updates

    Live Leadership Updates

    See more
    • Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

      Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 January 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announces that Travis Coy has been appointed as Executive Vice President (EVP), Chief Financial Officer and Head of Corporate Development, effective January 1, 2025. He will become an Exe

      1/2/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Levicept Appoints Eliot Forster as CEO

      Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur

      11/30/23 4:00:00 AM ET
      $IMCR
      $IMTX
      $PLX
      $FSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Immunocore Appoints Siddharth Kaul to its Board of Directors

      Immunocore Appoints Siddharth Kaul to its Board of Directors (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 June 2022) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, today announces the appointment of Siddharth (Sid) Kaul as a non-Executive member of its Board of Directors, effective June 8, 2022. Sid will serve as a Class II director and also serve as a member of the Audit and Remuneration committees. Sid is a s

      6/9/22 7:45:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Baker Bros. Advisors Lp bought $23,993,224 worth of American Depositary Shares (807,338 units at $29.72) (SEC Form 4)

      4 - Immunocore Holdings plc (0001671927) (Issuer)

      3/19/25 6:40:21 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Pao William

      4 - Immunocore Holdings plc (0001671927) (Issuer)

      2/27/25 4:31:08 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Pao William

      3 - Immunocore Holdings plc (0001671927) (Issuer)

      2/27/25 4:29:34 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    SEC Filings

    See more
    • SEC Form S-8 filed by Immunocore Holdings plc

      S-8 - Immunocore Holdings plc (0001671927) (Filer)

      5/7/25 4:38:41 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore Holdings plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Immunocore Holdings plc (0001671927) (Filer)

      5/7/25 7:33:58 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Immunocore Holdings plc

      10-Q - Immunocore Holdings plc (0001671927) (Filer)

      5/7/25 7:00:46 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care